State of Alaska Department of Revenue cut its position in shares of DaVita Inc. (NYSE:DVA – Free Report) by 9.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 6,859 shares of the company’s stock after selling 703 shares during the period. State of Alaska Department of Revenue’s holdings in DaVita were worth $689,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Parkside Financial Bank & Trust boosted its holdings in shares of DaVita by 88.6% in the 1st quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock worth $35,000 after purchasing an additional 147 shares during the period. Bessemer Group Inc. boosted its holdings in shares of DaVita by 55.1% in the 1st quarter. Bessemer Group Inc. now owns 445 shares of the company’s stock worth $36,000 after purchasing an additional 158 shares during the period. Mirova purchased a new position in shares of DaVita in the 1st quarter worth approximately $42,000. AlphaMark Advisors LLC boosted its holdings in DaVita by 66.0% during the 1st quarter. AlphaMark Advisors LLC now owns 528 shares of the company’s stock valued at $43,000 after acquiring an additional 210 shares during the period. Finally, CWM LLC boosted its holdings in DaVita by 78.1% during the 1st quarter. CWM LLC now owns 830 shares of the company’s stock valued at $67,000 after acquiring an additional 364 shares during the period. 84.69% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the company. StockNews.com assumed coverage on DaVita in a report on Thursday, October 5th. They set a “buy” rating for the company. UBS Group upgraded DaVita from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $100.00 to $142.00 in a report on Monday, August 7th. Finally, Truist Financial dropped their price objective on DaVita from $115.00 to $104.00 and set a “hold” rating for the company in a report on Wednesday, October 11th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, DaVita has a consensus rating of “Hold” and a consensus target price of $103.71.
DaVita Trading Up 3.7 %
Shares of NYSE DVA opened at $81.62 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 7.13. The business has a fifty day simple moving average of $96.34 and a two-hundred day simple moving average of $96.17. The firm has a market cap of $7.45 billion, a PE ratio of 15.75, a price-to-earnings-growth ratio of 0.82 and a beta of 0.95. DaVita Inc. has a twelve month low of $65.28 and a twelve month high of $116.97.
DaVita (NYSE:DVA – Get Free Report) last issued its earnings results on Thursday, August 3rd. The company reported $2.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.66 by $0.42. The business had revenue of $3 billion during the quarter, compared to analyst estimates of $2.95 billion. DaVita had a return on equity of 60.67% and a net margin of 3.98%. DaVita’s revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.30 EPS. Analysts expect that DaVita Inc. will post 7.38 earnings per share for the current fiscal year.
Insider Transactions at DaVita
In other news, insider Kathleen Alyce Waters sold 9,794 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $101.81, for a total value of $997,127.14. Following the completion of the transaction, the insider now directly owns 81,297 shares of the company’s stock, valued at approximately $8,276,847.57. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.40% of the company’s stock.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
- Five stocks we like better than DaVita
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 High Dividend Stocks To Beat Treasury Yields
- The 3 Best Blue-Chip Stocks to Buy Now
- United Airlines Shares Fall Despite Solid Quarter
- Stock Dividend Cuts Happen Are You Ready?
- Housing Starts Up, Homebuilders Down as Mortgage Rates Soar
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
